These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2095346)

  • 1. Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine.
    Ferry DG; Gazeley LR; Busby WJ; Beasley DM; Edwards IR; Campbell AJ
    Eur J Clin Pharmacol; 1990; 39(6):599-601. PubMed ID: 2095346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of cholestyramine on the elimination of tenoxicam and piroxicam.
    Guentert TW; Defoin R; Mosberg H
    Eur J Clin Pharmacol; 1988; 34(3):283-9. PubMed ID: 3260866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceleration of the elimination of tenoxicam by cholestyramine in the dog.
    Guentert TW; Schmitt M; Defoin R
    J Pharmacol Exp Ther; 1986 Jul; 238(1):295-301. PubMed ID: 3723402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of cholestyramine and activated charcoal on glipizide absorption.
    Kivistö KT; Neuvonen PJ
    Br J Clin Pharmacol; 1990 Nov; 30(5):733-6. PubMed ID: 2271372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oral cholestyramine on the elimination of high-dose methotrexate.
    Erttmann R; Landbeck G
    J Cancer Res Clin Oncol; 1985; 110(1):48-50. PubMed ID: 4019569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholestyramine as an adsorbent in acute lindane poisoning: a murine model.
    Kassner JT; Maher TJ; Hull KM; Woolf AD
    Ann Emerg Med; 1993 Sep; 22(9):1392-7. PubMed ID: 7689801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man.
    Busch U; Heinzel G; Narjes H
    Eur J Clin Pharmacol; 1995; 48(3-4):269-72. PubMed ID: 7589053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superactivated charcoal versus cholestyramine for cholesterol lowering: a randomized cross-over trial.
    Park GD; Spector R; Kitt TM
    J Clin Pharmacol; 1988 May; 28(5):416-9. PubMed ID: 3292601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of activated charcoal on the bioavailability of piroxicam in man.
    Laufen H; Leitold M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):48-52. PubMed ID: 3957490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure.
    Dordoni B; Willson RA; Thompson RP; Williams R
    Br Med J; 1973 Jul; 3(5871):86-7. PubMed ID: 4717848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam.
    Benveniste C; Striberni R; Dayer P
    Eur J Clin Pharmacol; 1990; 38(6):547-9. PubMed ID: 2373127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal dialysis of digoxin using cholestyramine.
    Rawashdeh NM; al-Hadidi HF; Irshaid YM; Battah AK
    Pharmacol Toxicol; 1993; 72(4-5):245-8. PubMed ID: 8372041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide.
    Neuvonen PJ; Kivistö K; Hirvisalo EL
    Br J Clin Pharmacol; 1988 Feb; 25(2):229-33. PubMed ID: 3358884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.
    Rudy AC; Figueroa NL; Hall SD; Brater DC
    Br J Clin Pharmacol; 1994 Jan; 37(1):1-5. PubMed ID: 8148211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the effect of repeated doses of oral activated charcoal on salicylate elimination.
    Ho JL; Tierney MG; Dickinson GE
    J Clin Pharmacol; 1989 Apr; 29(4):366-9. PubMed ID: 2723125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin.
    Bannwart B; Bertin P; Péhourcq F; Schaeverbeke T; Gillet P; Lefrançois G; Trèves R; Dehais J; Netter P; Gaucher A
    Int J Clin Pharmacol Ther; 2001 Jan; 39(1):33-6. PubMed ID: 11204935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the use of activated charcoal and cholestyramine for reducing the body burden of polybrominated biphenyls.
    McConnell EE; Harris MW; Moore JA
    Drug Chem Toxicol; 1980; 3(3):277-92. PubMed ID: 6256148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of tricyclic antidepressants with cholestyramine in vitro.
    Bailey DN; Coffee JJ; Anderson B; Manoguerra AS
    Ther Drug Monit; 1992 Aug; 14(4):339-42. PubMed ID: 1519310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.
    Said SA; Foda AM
    Arzneimittelforschung; 1989 Jul; 39(7):790-2. PubMed ID: 2783182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.